SPRY - ARS Pharmaceuticals - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

SPRY is currently covered by 2 analysts with an average price target of $28. This is a potential upside of $17.42 (338.87%) from yesterday's end of day stock price of $6.38.

ARS Pharmaceuticals's activity chart (see below) currently has 15 price targets and 15 ratings on display. The stock rating distribution of SPRY is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 22.56% with an average time for these price targets to be met of 335.86 days.

Highest price target for SPRY is $32, Lowest price target is $24, average price target is $28.

Most recent stock forecast was given by from LEERINK on 25-Jun-2026. First documented stock forecast 12-Dec-2022.

Best performing analysts who are covering SPRY - ARS Pharmaceuticals:

Andreas Argyrides Joshua Schimmer Louise Chen Ryan Deschner Roanna Ruiz

Currently out of the existing stock ratings of SPRY, 2 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 20-Sep-2024

$24

$15.46 (181.03%)

$27

Buy Since 25-Jul-2024

$32

$23.46 (274.71%)

$32

Buy Since 07-Mar-2025

$30

$21.93 (271.75%)

Buy Since 31-Jan-2023

$19

$10.95 (136.02%)

$13

Show more analysts

Please expand the browser size to see the chart

What is SPRY (ARS Pharmaceuticals) average time for price targets to be met?

On average it took 335.86 days on average for the stock forecasts to be realized with a an average price target met ratio 22.56

Which analyst has the current highest performing score on SPRY (ARS Pharmaceuticals) with a proven track record?

ANDREAS ARGYRIDES

Which analyst has the current lower performing score on SPRY (ARS Pharmaceuticals) with a proven track record?

ROANNA RUIZ

Which analyst has the most public recommendations on SPRY (ARS Pharmaceuticals)?

Andreas Argyrides works at CHARDAN CAPITAL and has 10 price targets and 7 ratings on SPRY

Which analyst is the currently most bullish on SPRY (ARS Pharmaceuticals)?

Ryan Deschner with highest potential upside - $26.35

Which analyst is the currently most reserved on SPRY (ARS Pharmaceuticals)?

Andreas Argyrides with lowest potential downside - $10.95

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?